INTRODUCTION {#S0001}
============

Routine exercise training of moderate intensity is known to enhance immune function \[[@CIT0027]\] and reduce risk of mortality \[[@CIT0011], [@CIT0023]\], cardiovascular diseases, obesity, and type 2 diabetes \[[@CIT0017]\]. However, an acute bout of prolonged (\>1.5 h) and/or strenuous exercise (55-75% maximal O~2~ uptake) has also been shown to provoke muscle damage/soreness \[[@CIT0004]\], and elicit an acute inflammatory \[[@CIT0015]\], oxidative stress \[[@CIT0007], [@CIT0009]\], and immunosuppressive response \[[@CIT0025]\] during the post-exercise recovery period. In order to alleviate these potential adverse responses following prolonged/strenuous exercise, the consumption of non-steroidal anti-inflammatory drugs (NSAIDs) has been strategically used to reduce soreness, muscle damage, and inflammation following exercise \[[@CIT0013]\].

The original NSAIDs (e.g. ibuprofen) inhibited both the constitutive cyclooxygenase (COX)-1 and the more inducible COX-2 enzyme, which both catalyze the generation of prostanoids \[prostaglandins (PGE2 and PGF2a), prostacyclins and thromboxanes\]; which are involved in numerous inflammatory, anaphylactic, and cardiovascular physiological processes \[[@CIT0014]\]. However, it has been postulated that COX-2 is the key enzyme which regulates the amount and duration of inflammatory cell accumulation \[[@CIT0029]\] and lipid peroxidation \[[@CIT0001]\] following exercise-induced muscle damage. Therefore, it seems plausible that the more recently developed selective COX-2 inhibitors may be more appropriate and specific to reduce excessive inflammatory reactions following exercise than the non-selective (COX-1 and COX-2) inhibitors \[[@CIT0028]\].

Celecoxib, a sulfonamide, is a selective COX-2 inhibitor that has anti-inflammatory and analgesic effects comparable to non selective NSAIDs, and presents with significantly less gastrointestinal toxicity \[[@CIT0028]\]. To date, several studies have demonstrated a lack of efficacy of NSAIDs treatment on muscle inflammation after exercise \[[@CIT0012], [@CIT0018], [@CIT0026]\], while others have reported enhanced recovery and reduction of inflammatory markers following exercise \[[@CIT0008]\]. Therefore, given the equivocal results regarding the effect of non-selective anti-inflammatory drugs on exercise-induced inflammation, muscle damage, and lipid peroxidation, this study was designed to investigate the influence of an acute low dose of the selective COX-2 inhibitor celecoxib on inflammation, muscle damage, and lipid peroxidation following an intense bout of aerobic exercise.

MATERIALS AND METHODS {#S0002}
=====================

Participants {#S20003}
------------

Twenty untrained male volunteers took part in this study. All subjects were informed verbally and in writing about the nature and demands of the study, and subsequently completed a health history questionnaire. Qualifying volunteers were provided with and asked to sign an institutionally approved informed consent form. In addition to meeting the health criteria, individuals engaging in the following were also excluded from the study: smoking, alcohol intake, vitamin supplementation (e.g., vitamin A, C and E) or NSAIDs. Three-day diet records were used to estimate subjects' average daily intake of vitamin A, C, and E prior to the beginning of the study. All subjects were untrained and had no known allergies to NSAIDs. Subjects were randomly assigned to treatment (T) (100 mg celecoxib) or placebo (P) groups. Each group was matched for height, weight, BMI, % fat and cardiovascular fitness (no significant group differences) ([Table 1](#T0001){ref-type="table"}). The protocol of the study was approved by the university ethics committee in accordance with the Helsinki Declaration.

###### 

SUBJECTS' CHARACTERISTICS IN TREATMENT (T) AND PLACEBO (P) GROUPS (N = 10)

  Group   VO~2~max (ml·kg^-1^·min^-1^)   BMI (kg·m^-2^)   Height (cm)   Body mass (kg)   Age (yrs)    Skin folds (mm)
  ------- ------------------------------ ---------------- ------------- ---------------- ------------ -----------------
  T       34.5 ± 2.8                     23.3 ± 2.7       176.6 ± 7.7   72.4 ± 8.6       25.7 ± 3.9   45.1 ± 6.4
  P       35.0 ± 5.2                     23.0 ± 1.1       178.2 ± 6.8   73.1 ± 5.7       25.3 ± 5.2   40.2 ± 8.4

Note: Data represent mean ± SD.

Dietary records {#S20004}
---------------

Subjects were asked to keep a dietary record of their food intake 3 days prior to the exercise test session. Total daily Vitamin A, C, and E intake during the 3 days prior to testing were determined using the Dietary Manager Computer program (Food process-2). Dietary analysis revealed no statistically significant differences in vitamin A, C, and E intake between groups ([Table 2](#T0002){ref-type="table"}).

###### 

MEAN TOTAL DIETARY INTAKE OF VITAMIN A, C, AND E OF SUBJECTS IN TREATMENT (T) AND PLACEBO (P) GROUPS

  Variable         group T         group P         P
  ---------------- --------------- --------------- ------
  Vitamin A (RE)   529.4 ± 384.3   570.1 ± 320.2   0.58
  Vitamin C (mg)   61.6 ± 26.3     45.9 ± 21.7     0.21
  Vitamin E (mg)   4.4 ± 2.6       3.4 ± 1.7       0.41

Note: Data represent mean ± SD.

Preliminary testing {#S20005}
-------------------

Cardiovascular fitness was determined by performing a maximal oxygen uptake test ($\overset{.}{\text{V}}$O~2~max test). $\overset{.}{\text{V}}$O~2~max was measured indirectly on a treadmill using the Bruce protocol. Briefly, subjects warmed up for 4 minutes at a speed of 3 mph on a 2.5% grade. Following warm-up, subjects ran on a treadmill beginning at a moderate pace; every 3 minutes the grade and intensity were increased until exhaustion \[[@CIT0003]\]. Heart rate was monitored by a Polar Vantage XL heart rate monitor (Polar Beat, Port Washington, NY, USA). This was conducted at least 2 weeks prior to the scheduled exercise session.

Experimental design and procedures {#S20006}
----------------------------------

On the morning of the trial, subjects arrived at the laboratory. They were instructed to have a standard breakfast consisting of two boiled eggs 2 h prior to the test. All subjects were required to avoid any strenuous exercise for 72 h prior to participation in the study. Participants performed a 10-min warm-up consisting of running at 50% $\overset{.}{\text{V}}$O~2~ max (5 min) and stretching (5 min). Following the warm-up and light stretching, participants ran on a treadmill for 30 min at 75% $\overset{.}{\text{V}}$ O~2~ max. Blood samples were taken from an antecubital forearm vein before exercise, immediately after, 3 h after, and 24 h after exercise. Each sample was taken following 15 min of standing in a resting position (except for the post-exercise sample, which was taken immediately upon cessation of exercise). Subjects consumed 100 mg of celecoxib or placebo immediately following exercise and 12 h after exercise.

Blood sampling and analysis {#S20007}
---------------------------

Approximately 6 ml of whole blood was withdrawn at each time point. 1.5 ml from each sample was added to tubes containing ethylenediaminetetra-acetic acid (EDTA) for determination of leukocyte differentials using a cell counter (K-1000 Sysmax, Japan). Haemoglobin and haematocrit concentrations from whole blood samples were used to estimate plasma volume shifts. All post-exercise samples were corrected for plasma volume change according to the methods of Dill and Costill \[[@CIT0005]\]. 4.5 ml of the blood was allowed to clot at 37.5°C, and centrifuged at 5,000 g for 30 min. Serum was prepared according to standard methods. Serum creatine kinase (CK) was determined using commercially available methods (Roche Hittachi-911 Chemistry Autoanalizer, Germany and Japan). Serum CRP was measured by a nephelometric procedure using commercially available kits (Minineph, ZK044. L.R, Birmingham, UK). For malondialdehyde (MDA) measurement, 0.05 ml serum was added to 0.25 ml of 0.1M TCA and 0.7 ml distilled water, vortexed in a 1.5 ml centrifuge tube for 10 s, centrifuged at 4500 g for 5 min and used for high performance liquid chromatography (HPLC) (Jasco, Japan) analysis \[[@CIT0010]\].

Statistical analysis {#S20008}
--------------------

All data are expressed as means ± SD. A two (groups) x four (time) analysis of variance (ANOVAs) with repeated measures on time was used to compare group, time, and group x time interactions for each variable. Significant interactions were further explored using a Bonferroni correction analysis. The significance level for this study was set at P \< 0.05 for all tests.

RESULTS {#S0009}
=======

Effect of exercise on markers of inflammation {#S20010}
---------------------------------------------

Leukocyte, neutrophil, monocyte and lymphocyte counts, and CRP concentrations before, immediately after, 3 h after, and 24 h after exercise are shown in [Table 3](#T0003){ref-type="table"}. Total leukocyte and neutrophil counts were significantly increased 3 h after exercise in both groups and returned to pre-exercise values 24 h after exercise (P \< 0.05). Lymphocyte counts decreased significantly 3 h after exercise in both groups (P \< 0.05). There were no significant changes in monocyte counts in either group (P \> 0.05). Serum CRP concentration increased significantly immediately after exercise and remained elevated for 24 h after exercise in both groups (P \< 0.05). However, no significant changes were found for total leukocyte, neutrophil, monocyte and lymphocyte counts, or CRP concentration between groups (P \> 0.05).

###### 

TOTAL LEUKOCYTE, NEUTROPHIL AND MONOCYTE COUNT

  Parameters                         Groups          Pre                                            Post                                              3h                                                24h
  ---------------------------------- --------------- ---------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------------------------
  Total leukocyte count (n·L^-1^)    P               6528 ± 993.1                                   7154 ± 1219.4                                     9720 ± 1353.5[\*](#TF0001){ref-type="table-fn"}   6321 ± 1088.3
  T                                  7071 ± 1003.2   7594 ± 1640.9                                  9167 ± 1780.9[\*](#TF0001){ref-type="table-fn"}   6648 ± 1442.5                                     
                                                                                                                                                                                                        
  Blood neutrophil count (n·L^-1^)   P               3540 ± 734.9                                   4161 ± 841.2                                      6660 ± 1492.7[\*](#TF0001){ref-type="table-fn"}   3386 ±775.2
  T                                  3798 ±951.3     4249 ± 1407.6                                  5935 ± 1605.5[\*](#TF0001){ref-type="table-fn"}   3669 ± 971.7                                      
                                                                                                                                                                                                        
  Blood monocyte count (n·L^-1^)     P               394 ± 102.3                                    460 ± 100.0                                       527 ± 81.65                                       385 ± 104.9
  T                                  467 ± 128.3     459 ± 114.4                                    545 ± 130.3                                       464 ± 156.8                                       
                                                                                                                                                                                                        
  Blood lymphocyte count (n·L^-1^)   P               2266 ± 589.2                                   2220 ± 631.2                                      2252 ± 478.8[†](#TF0002){ref-type="table-fn"}     2200 ± 567.5
  T                                  2441 ± 401.9    2525 ± 687.1                                   2401 ± 646.3[†](#TF0001){ref-type="table-fn"}     2167 ± 615.3                                      
                                                                                                                                                                                                        
  CRP (mg·L^-1^)                     P               2.0 ± 0.7                                      2.68 ± 0.68[\*](#TF0001){ref-type="table-fn"}     3.31 ± 1.03[\*](#TF0001){ref-type="table-fn"}     4.19 ± 1.0[\*](#TF0001){ref-type="table-fn"}
  T                                  1.96 ± 0.6      2.51 ± 0.4[\*](#TF0001){ref-type="table-fn"}   3.12 ± 0.6[\*](#TF0001){ref-type="table-fn"}      4.17 ± 1.2[\*](#TF0001){ref-type="table-fn"}      

Note: Data represent mean ± SD.

Indicates significant difference from pre-exercise in both groups (P \< 0.05).

Indicates decrease of lymphocytes compared with pre-exercise in both groups (P \< 0.05).

Markers of Muscle Damage and Oxidative Stress Following Exercise:

Serum CK activity were significantly increased immediately after, 3 h after, and 24 h after exercise in both groups (P \< 0.05) ([Figure 1](#F0001){ref-type="fig"}). Serum MDA concentrations were significantly elevated immediately after exercise in both groups (P \< 0.05) ([Figure 2](#F0002){ref-type="fig"}). However, there were no significant differences in CK or MDA concentration between groups (P \> 0.05) ([Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}).

![SERUM CK ACTIVITY BEFORE AND AFTER EXERCISE\
Note: \* Indicates significant increase compared with pre-exercise in both groups (P \< 0.05). Values represent means ± SD (n = 10). P: placebo, T: treatment.](JBS-30-1029824-g001){#F0001}

![SERUM MDA CONCENTRATION BEFORE AND AFTER EXERCISE\
Note: \* Indicates significant increase compared with pre-exercise in both groups (P \< 0.05). Values represent means ± SD (n = 10). P: placebo, T: treatment.](JBS-30-1029824-g002){#F0002}

DISCUSSION {#S0010}
==========

The purpose of this study was to assess the effect of acute low-dose celecoxib administration on exercise-induced inflammation, muscle damage and lipid peroxidation markers following intensive aerobic exercise. To date, the efficacy of NSAIDs treatment on muscle damage, inflammation, and lipid peroxidation remains unclear. The equivocal results between studies, some demonstrating no effect \[[@CIT0012], [@CIT0018], [@CIT0026]\], and others reporting a reduction in inflammatory markers following exercise \[[@CIT0008]\], make it difficult to determine if NSAIDs provide protection against exercise-induced muscle damage and inflammation. In the present study, we used a selective COX-2 inhibitor and found no significant differences in all inflammatory markers between groups and each time period. These findings suggest that post-exercise administration of celecoxib does not prevent or alleviate exercise-induced inflammation.

There are several possible explanations for the lack of efficacy of celecoxib administration on inflammation markers in the present study compared with other studies: Celecoxib is a single-action NSAID blocking the COX-2 pathway and has no effect on COX-1 and lipoxygenase (LIPOX) pathways of arachidonic acid (AA) metabolism. Therefore, it has been proposed that celecoxib may not prevent the delayed COX-1 or the LIPOX induced inflammation and drift of AA metabolism towards this pathway, leading to muscle damage and inflammation \[[@CIT0022]\]. Secondly, a typical sign of acute inflammation is an increase in total leukocyte count, which occurs within a few hours after muscle damage \[[@CIT0027]\]. Evidence suggests that the inflammatory response following exercise is distinctly different from those accompanying infection or tissue injury \[[@CIT0016]\]. Therefore, physical exercise can be regarded as a prototype of physical stress which induces a pattern of hormonal and immunological responses that is similar to, yet distinctly different from, clinical physical stressors (e.g. surgery, trauma and sepsis). Finally, it is also possible that the concentration of celecoxib at the site of the injury in this study was insufficient to have caused a significant anti-inflammatory effect following the exercise protocol.

In the present study, CK activity, an indirect qualitative index of muscle damage, was significantly elevated immediately after, 3 h after, and 24 h after exercise in both groups. There was no significant difference between the two groups, which suggests a lack of efficacy of celecoxib administration on CK induced from exercise. In agreement with the present study, Hasson et al. \[[@CIT0008]\] and Donnelly et al. \[[@CIT0006]\] reported that NSAIDs had no effect on CK levels following exercise. In contrast, Pizza et al. \[[@CIT0019]\] and Tokmakidis et al. \[[@CIT0026]\] found significantly lower post-exercise CK concentration in individuals consuming NSAIDs. These discrepant findings between studies highlight the need for further research to understand the underlying physiological mechanisms between NSAID consumption and exerciseinduced muscle damage. Future work should incorporate rigorously controlled dietary and NSAID intake prior to and following exercise; this would enable better comparisons between studies.

It has been well documented that both prolonged and intense exercise cause a marked rise in oxidative stress biomarkers \[[@CIT0007], [@CIT0021]\]. Potential sources of elevated reactive oxygen species (ROS) during exercise include mitochondria, NADPH oxidases, and xanthine oxidases derived from both skeletal muscle and phagocytic cells \[[@CIT0020]\]. Similar to the aforementioned studies, we demonstrated a significant increase in circulating MDA immediately after exercise. We predicted that celecoxib administration would diminish both the immune and oxidative stress response; however, this did not occur. Current exercise and non-exercise data have not provided a clear explanation regarding the efficacy of both selective COX-2 and non-selective COX-2 inhibitors for preventing or attenuating oxidative stress \[[@CIT0012]\]. Exercise and non-exercise studies have shown the ability of the nonselective COX-2 inhibitor aspirin (acetylsalicylic acid) to reduce the post-exercise oxidative stress response, decrease vascular (O~2~ ^-^.) production, and attenuate angiotensin II-induced oxidative stress \[[@CIT0024]\], whereas selective COX-2 inhibition has been shown to attenuate oxidative stress in the non-exercise setting but not following exercise \[[@CIT0012], [@CIT0013]\]. In fact, McAnulty et al. demonstrated an increased post-exercise oxidative stress response following NSAID intake compared to controls \[[@CIT0012], [@CIT0013]\]. While the potential mechanisms remain to be determined, it has been hypothesized that NSAID use along with strenuous exercise may actually increase gut permeability and enhance endotoxin leakage from the gut into the blood, resulting in inflammation and oxidative stress \[[@CIT0002]\]. Given the equivocal findings regarding selective and non-selective COX-2 inhibition on exerciseinduced inflammation and oxidative stress, it is premature to decide whether NSAIDs should be used during exercise as a therapy to combat the inflammatory and oxidative stress response to exercise. Further research should be performed to provide a mechanistic explanation as to why results differ between studies.

CONCLUSIONS {#S0011}
===========

In conclusion, our results indicate that celecoxib use following exercise does not alleviate inflammation, muscle damage, or oxidative stress. The relationship between selective and non-selective COX-2 inhibitors and muscle damage, inflammation, and oxidative stress should be further explored in future studies.
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